FDA PMA FDA Class 2 30-Day Notice Accepted 🇺🇸 United States

Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus

PMA: P020011 · Supplement: S010 · Decision Nov 3, 2017
Classifications
1
FEI Numbers
10
Registration Numbers
10

Basic Information

Device Name
Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus
Trade Name
Aptima HCV RNA Qualitative Assay
PMA Number
P020011
Supplement Number
S010
Device Class
FDA Class 2
Product Code
MZP
Generic Name
Assay, hybridization and/or nucleic acid amplification for detection of hepatitis c rna,hepatitis c virus
Regulation Number
866.3170
Medical Specialty
Microbiology
Advisory Committee
Microbiology
Decision
30-Day Notice Accepted
Decision Code
OK30
Decision Date
November 3, 2017
Date Received
October 10, 2017
Supplement Type
30-Day Notice
Supplement Reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Expedited Review
N

Advisory Committee Statement

Relocate manufacturing equipment within a manufacturing site.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
MZP Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus